PLUS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.8 USD | +4.65% |
|
+8.11% | +2.85% |
| Sales 2024 * | 3.4M 271M | Sales 2025 * | 4.28M 341M | Capitalization | 7.7M 613M |
|---|---|---|---|---|---|
| Net income 2024 * | -19M -1.51B | Net income 2025 * | -22M -1.75B | EV / Sales 2024 * | 2.26 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.8 x |
| P/E ratio 2024 * |
-0.79
x | P/E ratio 2025 * |
-0.96
x | Employees | 20 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.77% |
More Fundamentals
* Assessed data
More news
Latest transcript on Plus Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +4.65% | ||
| 1 week | +8.11% | ||
| Current month | +3.42% | ||
| 1 month | -3.74% | ||
| 3 months | -8.16% | ||
| 6 months | +32.35% | ||
| Current year | +2.85% |
1 week
1.65
1.92
1 month
1.521.97
Current year
1.522.35
1 year
0.975.09
3 years
0.9753.10
5 years
0.97343.35
10 years
0.97286 312.14
| Managers | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 61 | 30/09/02 |
Andrew Sims
DFI | Director of Finance/CFO | 51 | 05/02/20 |
Pius Maliakal
CTO | Chief Tech/Sci/R&D Officer | - | 26/07/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 61 | 30/09/02 |
Richard Hawkins
CHM | Chairman | 75 | 30/11/07 |
Robert Lenk
BRD | Director/Board Member | 75 | 29/02/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/05/24 | 1.8 | +4.65% | 51,657 |
| 01/05/24 | 1.72 | -1.18% | 5,019 |
| 30/04/24 | 1.74 | +4.85% | 7,592 |
| 29/04/24 | 1.66 | -1.78% | 8,726 |
| 26/04/24 | 1.69 | +1.50% | 16,331 |
Delayed Quote Nasdaq, May 02, 2024 at 09:30 pm
More quotes
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
Calendar
11/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.8
USD
Average target price
16.5
USD
Spread / Average Target
+816.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.85% | 7.7M | |
| +26.28% | 48.09B | |
| -3.99% | 40.43B | |
| +46.85% | 40.62B | |
| -6.20% | 28.36B | |
| +6.36% | 24.89B | |
| -21.47% | 19.01B | |
| +27.58% | 12.09B | |
| -2.75% | 11.8B | |
| -2.02% | 11.88B |
- Stock Market
- Equities
- PSTV Stock
